Mitochondrion

Mission Therapeutics announces publication in Nature Communications outlining potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson's Disease

Retrieved on: 
Monday, November 13, 2023
Parkinson's disease, Research, Alpha-synuclein, Therapy, Pathology, PD, Mouse, Patient, Mission, Dopamine, Ubiquitin, Neuron, Nature Communications, University of Cambridge, Harvard Medical School, Mitochondrion, Human, Death, Disability, Biomarker, Cell, Mitophagy, Pharmaceutical industry, Palladium, Disease

CAMBRIDGE, England, Nov. 13, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces the publication of a peer-reviewed article titled 'Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's Disease (PD) mouse model' in the journal Nature Communications, which can be viewed here. The research was the result of collaborative work between Cambridge University, Harvard Medical School, and Mission Therapeutics.

Key Points: 
  • Mission Therapeutics is a global leader in discovering and developing innovative therapeutics that promote mitophagy.
  • By inhibiting the enzyme USP30, Mission's experimental drug MTX325 helps promote mitochondrial quality control by increasing the removal of dysfunctional mitochondria.
  • Dr Anker Lundemose, Chief Executive Officer at Mission Therapeutics, said: "The exciting findings of this Nature Communications paper are a tremendous boost to Mission's Parkinson's Disease programme.
  • The Nature Communications paper outlines how Mission's drug MTX325 has potential as a novel, disease-modifying treatment for Parkinson's, by enhancing mitophagy and clearing dysfunctional mitochondria.

Mission Therapeutics announces publication in Nature Communications outlining potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson's Disease

Retrieved on: 
Monday, November 13, 2023
Parkinson's disease, Research, Alpha-synuclein, Therapy, Pathology, PD, Mouse, Patient, Mission, Dopamine, Ubiquitin, Neuron, Nature Communications, University of Cambridge, Harvard Medical School, Mitochondrion, Human, Death, Disability, Biomarker, Cell, Mitophagy, Pharmaceutical industry, Palladium, Disease

CAMBRIDGE, England, Nov. 13, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces the publication of a peer-reviewed article titled 'Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's Disease (PD) mouse model' in the journal Nature Communications, which can be viewed here. The research was the result of collaborative work between Cambridge University, Harvard Medical School, and Mission Therapeutics.

Key Points: 
  • Mission Therapeutics is a global leader in discovering and developing innovative therapeutics that promote mitophagy.
  • By inhibiting the enzyme USP30, Mission's experimental drug MTX325 helps promote mitochondrial quality control by increasing the removal of dysfunctional mitochondria.
  • Dr Anker Lundemose, Chief Executive Officer at Mission Therapeutics, said: "The exciting findings of this Nature Communications paper are a tremendous boost to Mission's Parkinson's Disease programme.
  • The Nature Communications paper outlines how Mission's drug MTX325 has potential as a novel, disease-modifying treatment for Parkinson's, by enhancing mitophagy and clearing dysfunctional mitochondria.

Promontory Therapeutics Presents Data on Molecular Mechanisms of PT-112's Immunogenic Effects

Retrieved on: 
Saturday, November 4, 2023
Society for Immunotherapy of Cancer, Mitochondrion, Immunogenic cell death, ICD, Bax, Northern blot, Doctor of Philosophy, Phosphorylation, Bcl-2, SITC, Cancer immunotherapy, Immunotherapy, Reactive oxygen species, ISR, Research and development, Cancer, Flow cytometry, Annual general meeting, Weill Cornell Medicine, Lung cancer, Endoplasmic reticulum, Society, Therapy, Patient, Cytosol, DNA, Vaccine, Platinum, Research

NEW YORK, Nov. 4, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a Phase 2 stage biotech company advancing immunogenic small molecule approaches in oncology, today presented data demonstrating the molecular mechanism of its lead therapeutic candidate, PT-112, and its ability to induce immunogenic cell death (ICD) in cancer cells. Data suggest that PT-112-induced ICD is mediated by endoplasmic reticulum (ER) and mitochondrial stresses, which are specific intra-cellular events that comprise part of the larger ICD mechanism. The presentation was made at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego.

Key Points: 
  • Data suggest that PT-112-induced ICD is mediated by endoplasmic reticulum (ER) and mitochondrial stresses, which are specific intra-cellular events that comprise part of the larger ICD mechanism.
  • The presentation was made at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego.
  • PT-112 effects on mitochondria included increases in mitochondrial mass and reactive oxygen species, changes in membrane polarization, and the release of mitochondrial DNA into the cytosol, a potent immunogenic signal.
  • For more information about Promontory Therapeutics and PT-112, visit www.PromontoryTx.com .

Mission Therapeutics to Present Abstract at American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, November 2, 2023
Kidney, Mitophagy, Trial of the century, Mission, Mitochondrion, Therapy, Treatment, DUB, Acute kidney injury, AKI, Society, Risk, Master of Science, Pharmacology, Nephrology, Safety, Patient, American Society of Nephrology, MS, Simulation, Pharmaceutical industry

CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.

Key Points: 
  • CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.
  • Mission Therapeutics is a world leader in discovering and developing novel therapeutics which promote the removal of dysfunctional mitochondria to maintain cell health and function.
  • The American Society of Nephrology is a major organization working toward a goal of a world without kidney diseases and we are excited to have the opportunity to share our progress at this important conference.
  • A Phase II trial of MTX652 in patients at risk of acute kidney injury following cardiac surgery is planned to start in Q1 2024.

Mission Therapeutics to Present Abstract at American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, November 2, 2023
Kidney, Mitophagy, Trial of the century, Mission, Mitochondrion, Therapy, Treatment, DUB, Acute kidney injury, AKI, Society, Risk, Master of Science, Pharmacology, Nephrology, Safety, Patient, American Society of Nephrology, MS, Simulation, Pharmaceutical industry

CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.

Key Points: 
  • CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.
  • Mission Therapeutics is a world leader in discovering and developing novel therapeutics which promote the removal of dysfunctional mitochondria to maintain cell health and function.
  • The American Society of Nephrology is a major organization working toward a goal of a world without kidney diseases and we are excited to have the opportunity to share our progress at this important conference.
  • A Phase II trial of MTX652 in patients at risk of acute kidney injury following cardiac surgery is planned to start in Q1 2024.

ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease

Retrieved on: 
Wednesday, October 25, 2023
Inflammasome, HADHA, Plasma, Mitochondrion, ASC, Pulmonary fibrosis, Myocardial injury after non-cardiac surgery, Obesity, Human, Inflammation, Research, Mouse, Cardiac fibrosis, Scar, Magnetic resonance imaging, Therapy, Super Meat Boy, Cardiovascular disease, Pharmaceutical industry, Meat, NLRP3, Diabetes

Inflammasome ASC localized in the heart’s mitochondria participates in NLRP3 inflammasome formation and activation based on mouse data.

Key Points: 
  • Inflammasome ASC localized in the heart’s mitochondria participates in NLRP3 inflammasome formation and activation based on mouse data.
  • “The research published in Diabetes demonstrates that ASC in the heart’s mitochondria facilitates NLRP3 inflammasome assembly and activation leading to damaging inflammation and myocardial fibrosis associated with obesity.
  • By inhibiting ASC, IC 100 blocks formation of NLRP3 and other types of inflammasomes to block initiation of the inflammatory cascade.
  • To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here .

A Game Changer: Exerkine Corporation Leap Frogs into its Commercial Phase

Retrieved on: 
Tuesday, October 17, 2023
Cardiovascular disease, Patent, Type 2 diabetes, FRCP, Partnership, News, The Wall Street Journal, Doctor of Philosophy, McMaster University, Obesity, CSO, Weight loss, Mitochondrion, Dementia, Safety, Hospital, Bell, Therapy, Facial muscles, ABC News, Clinical trial, CBC News, Exercise, Science, Skeletal muscle, DSM-IV codes, Business development, Research, Interleukin, Cognition, Pharmaceutical industry, Dietary supplement, The New York Times, MD

HAMILTON, Ontario, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Exerkine Corporation (the "Company" or "Exerkine") is pleased to announce that it has successfully transitioned from its pre-revenue development phase into commercial operations.

Key Points: 
  • HAMILTON, Ontario, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Exerkine Corporation (the "Company" or "Exerkine") is pleased to announce that it has successfully transitioned from its pre-revenue development phase into commercial operations.
  • Exerkine is poised to change this paradigm through proprietary products that are built and backed by science.
  • Utilizing advances in mitochondrial sciences, exercise physiology, and nutrition, Exerkine leverages pharmaceutical-industry R&D standards to create novel nutrition-based products.
  • As the founder, CEO and CSO of Exerkine, Dr. Tarnopolsky is applying his clinical and scientific expertise to lead Exerkine’s commercial and research development.

IBN Announces Latest Episode of The Bell2Bell Podcast featuring Rob Etherington, CEO of Clene Inc.

Retrieved on: 
Tuesday, October 10, 2023
Diagnosis, ALS, Etherington, Mitochondrion, Johnson & Johnson, Disease, IBN, FDA, Actelion, Growth, Podcast, Housekeeping, Science, Interview, Multiple sclerosis, CNM, Pfizer, Patient, Sale, Pharmaceutical industry, Management

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries.

Key Points: 
  • The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries.
  • Bell2Bell’s latest podcast features Rob Etherington, President and CEO of Clene Inc. , a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.
  • To begin the interview, Etherington provided an introduction to Clene’s business model and discussed recent developments providing hope to those affected by neurodegenerative conditions.
  • The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series .

Mission Therapeutics to Present at Michael J. Fox Foundation's 15th Annual Parkinson's Disease Therapeutics Conference

Retrieved on: 
Tuesday, October 10, 2023
The Michael J. Fox Foundation, Mitochondrial disease, Research, Biology, Mitochondrion, Therapy, Neuron, PINK1, MJFF, Protein, DUB, PD, Mitophagy, CNS, Parkinson's disease, Conference, Patient, Parkinson, Pharmaceutical industry, Disease

Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.

Key Points: 
  • Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.
  • Fox Foundation (MJFF) is dedicated to accelerating a cure for Parkinson's Disease and improved therapies for those living with the condition today.
  • A major unmet need for Parkinson's Disease patients is a treatment that slows or prevents the progression of disease.
  • Mission Therapeutics is currently developing two DUB inhibitors: MTX325 (targeting the CNS) and MTX652 (peripheral) which can potentially be used to treat any disease driven by mitochondrial dysfunction.

Mission Therapeutics to Present at Michael J. Fox Foundation's 15th Annual Parkinson's Disease Therapeutics Conference

Retrieved on: 
Tuesday, October 10, 2023
The Michael J. Fox Foundation, Mitochondrial disease, Research, Biology, Mitochondrion, Therapy, Neuron, PINK1, MJFF, Protein, DUB, PD, Mitophagy, CNS, Parkinson's disease, Conference, Patient, Parkinson, Pharmaceutical industry, Disease

Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.

Key Points: 
  • Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.
  • Fox Foundation (MJFF) is dedicated to accelerating a cure for Parkinson's Disease and improved therapies for those living with the condition today.
  • A major unmet need for Parkinson's Disease patients is a treatment that slows or prevents the progression of disease.
  • Mission Therapeutics is currently developing two DUB inhibitors: MTX325 (targeting the CNS) and MTX652 (peripheral) which can potentially be used to treat any disease driven by mitochondrial dysfunction.